Version history

{
  "session_id": "sess_AD-MASTER-PLAN-TREM2-20260428030753_task_66f1207e_ctx",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread requires proximal validation\",\n      \"description\": \"The debate supports carrying forward TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread only if a proximal endpoint changes before the late outcome. The decisive validation path is: stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints.\",\n      \"target_gene\": \"TREM2\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.57,\n        \"novelty\": 0.64,\n        \"feasibility\": 0.69,\n        \"therapeutic_potential\": 0.58,\n        \"mechanistic_plausibility\": 0.67,\n        \"druggability\": 0.5,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.63,\n        \"reproducibility\": 0.66\n      },\n      \"composite_score\": 0.604,\n      \"evidence_for\": [\n        {\n          \"claim\": \"Preregistered claim: TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD progression\",\n          \"source\": \"AD-MASTER-PLAN-TREM2-20260428030753\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"TREM2 activation can be stage-dependent and may worsen inflammatory injury outside the right disease window\",\n          \"source\": \"AD-MASTER-PLAN-TREM2-20260428030753\"\n        }\n      ]\n    },\n    {\n      \"title\": \"Stratified falsifiers should govern AD Master Plan preregistration: TREM2\",\n      \"description\": \"Claims from this analysis should be evaluated across TREM2, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.\",\n      \"target_gene\": \"AD\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.54,\n        \"novelty\": 0.59,\n        \"feasibility\": 0.74,\n        \"therapeutic_potential\": 0.5,\n        \"mechanistic_plausibility\": 0.61,\n        \"druggability\": 0.43,\n        \"safety_profile\": 0.59,\n        \"competitive_landscape\": 0.53,\n        \"data_availability\": 0.68,\n        \"reproducibility\": 0.7\n      },\n      \"composite_score\": 0.591,\n      \"evidence_for\": [\n        {\n          \"claim\": \"The analysis question names specific entities or evaluation structure.\",\n          \"source\": \"AD-MASTER-PLAN-TREM2-20260428030753\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"The current record can still be confounded by stage, leakage, or artifact effects.\",\n          \"source\": \"AD-MASTER-PLAN-TREM2-20260428030753\"\n        }\n      ]\n    },\n    {\n      \"title\": \"TREM2 should remain under review until replicated\",\n      \"description\": \"The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.\",\n      \"target_gene\": \"tau\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.52,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.71,\n        \"therapeutic_potential\": 0.52,\n        \"mechanistic_plausibility\": 0.58,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.58,\n        \"competitive_landscape\": 0.52,\n        \"data_availability\": 0.65,\n        \"reproducibility\": 0.69\n      },\n      \"composite_score\": 0.577,\n      \"evidence_for\": [\n        {\n          \"claim\": \"Concrete next test: stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints\",\n          \"source\": \"AD-MASTER-PLAN-TREM2-20260428030753\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"Promotion before replication would weaken quality control.\",\n          \"source\": \"AD-MASTER-PLAN-TREM2-20260428030753\"\n        }\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"AD-MASTER-PLAN-TREM2-20260428030753\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"TREM2\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    },\n    {\n      \"source_id\": \"AD-MASTER-PLAN-TREM2-20260428030753\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"AD\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    },\n    {\n      \"source_id\": \"AD-MASTER-PLAN-TREM2-20260428030753\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"tau\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    },\n    {\n      \"source_id\": \"AD-MASTER-PLAN-TREM2-20260428030753\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"amyloid\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    }\n  ],\n  \"synthesis_summary\": \"Consensus: AD Master Plan preregistration: TREM2 is substantive enough for debate because it names TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread and can be tied to a concrete validation path: stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints. Dissent: TREM2 activation can be stage-dependent and may worsen inflammatory injury outside the right disease window. The claim should remain under review until the falsifier or replication path is executed.\"\n}",
  "tokens_used": "1359",
  "persona_id": "persona-synthesizer"
}